Emergent BioSolutions (EBS) Signs $911M CDC Follow-On Contract for Anthrax Vaccine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Emergent BioSolutions to Support HHS Anthrax Preparedness Strategy With Up to $1 Billion in BioThrax Deliveries to the Strategic National Stockpile
December 8, 2016 5:13 PM ESTCompany signs follow-on contract with CDC valued at up to $911 million to supply to the SNS approximately 29.4 million doses of BioThrax through September 2021BARDA issues notice of intent to separately procure approximately $100 million of BioThrax for the SNS over 24 months from contract award, which is expected in 1H 2017These actions, together with the recently awarded BARDA contract for NuThrax, reflect the U.S. governments intention to transition the stockpile of anthrax vaccines from BioThrax to NuThraxCompany re-establishes 2016 financial guidance
GAITHERSBURG, Md., Dec. 08, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc.... More
